TD Cowen analyst Yaron Werber has maintained their bullish stance on UPB stock, giving a Buy rating today.
Yaron Werber’s rating is based on several promising developments at Upstream Bio, Inc. The company has made significant progress with its lead asset, verekitug, which is being tested in multiple clinical trials for conditions such as asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). The completion of enrollment in the Phase 2 VIBRANT trial for CRSwNP and the anticipated data release in the second half of 2025 are crucial milestones that could lead to regulatory discussions and preparations for Phase 3 trials.
Furthermore, the positive Phase 3 data from competitors’ similar treatments, such as AMGN/AZN’s Tezspire, which targets the same TSLP mechanism, provide a favorable outlook for verekitug. Additionally, the company’s financial position is strong, with a successful IPO raising approximately $293 million and a cash reserve of $471 million, which supports ongoing and future research and development activities. These factors collectively contribute to Werber’s Buy rating for Upstream Bio, Inc.